1.2 Capital

Conexeu is developing a patented, clinically validated collagen scaffold platform that enables a new class of aesthetic and wound care products. Delivered as a liquid skin substitute that naturally gels in the body in approximately 10 minutes, the technology overcomes key limitations of existing dermal fillers, grafts, and implants, including toxicity, inflammation, invasiveness, and inconsistent outcomes. The company has secured strong global intellectual property with patents granted in the U.S., Japan, Europe, Australia, and Canada, supported by more than $4.5 million and over 10 years of research and development. Clinically proven in pilot studies, Conexeu’s non-toxic, non-surgical solution aligns with growing demand for minimally invasive regenerative treatments.

The platform addresses two large and growing markets with a single scalable product. In aesthetics, an $8.25 billion market, Conexeu targets dermal fillers, hand fillers, and large-volume body contouring, offering a safer and more versatile alternative to current options. In wound care, a $22.5 billion market, the scaffold promotes cellular regeneration and improved healing compared to traditional collagen products. An accelerated regulatory pathway, including 510(k) eligibility, significantly reduces cost and time to market, while multiple indications diversify risk and expand upside potential. Supported by leading academic institutions, healthcare partners, and multiple innovation awards, Conexeu represents a differentiated, IP-protected regenerative medicine opportunity with strong commercialization potential.